Journals / Klinik Psikofarmakoloji Bülteni / 2015 / Cilt: 25 - Sayı: 2

No association of catechol-O-methyltransferase (COMT) gene haplotypes in patients with schizophrenia in a Turkish sample

Pages
129–135
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: COMT rs2075507, rs4680, rs165599 SNPs and haplotypes do not appear to be risk factors for schizophrenia in this population.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The dopaminergic system, especially variations in the catechol-O-methyltransferase (COMT) gene, is of major interest in the etiology of schizophrenia.
📊
Key Findings & Data:The rs4680 (Val108/158Met), rs165599, and P2 promoter rs2075507 single nucleotide polymorphisms (SNPs) in the COMT gene have been shown to be associated with alteration of COMT gene expression and COMT enzyme activity.
💡
Conclusion & Impact:Conclusion: COMT rs2075507, rs4680, rs165599 SNPs and haplotypes do not appear to be risk factors for schizophrenia in this population.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The dopaminergic system, especially variations in the catechol-O-methyltransferase (COMT) gene, is of major interest in the etiology of schizophrenia. The rs4680 (Val108/158Met), rs165599, and P2 promoter rs2075507 single nucleotide polymorphisms (SNPs) in the COMT gene have been shown to be associated with alteration of COMT gene expression and COMT enzyme activity. The aim of this study was to investigate a possible association between schizophrenia and the haplotypes of these polymorphisms. Methods: The sample was comprised of 181 patients with schizophrenia and 368 healthy controls. The patients' psychotic symptoms were rated using the Positive and Negative Symptom Scale (PANSS). COMT rs2075507, rs4680, and rs165599 SNPs were evaluated by a polymerase chain reaction, followed by restriction fragment length polymorphism analysis. These SNPs in the COMT gene were subjected to haplotype analyses using Haploview ver. 4.2. Results: No significant differences were found between COMT rs2075507, rs4680, and rs165599 SNPs in schizophrenic patients and controls. The patients' PANSS results were not associated with these SNPs. No associations were obtained between 2 and 3-haplotypes of rs2075507, rs4680, rs165599 SNPs and schizophrenia. Conclusion: COMT rs2075507, rs4680, rs165599 SNPs and haplotypes do not appear to be risk factors for schizophrenia in this population.

🔖

Cite This Article

ALTINYAZAR, V., KİRCİ, C., TİNAZ, E., GUNDERİCİ, A. (2022). No association of catechol-O-methyltransferase (COMT) gene haplotypes in patients with schizophrenia in a Turkish sample. Klinik Psikofarmakoloji Bülteni, Cilt: 25 - Sayı: 2, 129–135. https://ajindex.com/articles/573968

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Danielyan A, Nasrallah HA. Neurological disorders in schizophrenia. Psychiatric Clinics of North America 2009
  2. 32(4):719-57. [CrossRef] 2. Sawa A, Snyder SH. Schizophrenia: Diverse Approaches to a Complex Disease. Science 2002
  3. 296(5568):692-5. [CrossRef] 3. Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician 2007
  4. 75(12):1821-9. 4. Lindsay EA, Goldberg R, Jurecic V, Morrow B, Carlson C, Kucherlapati RS, et al. Velo-cardio-facial syndrome: frequency and extent of 22q11 deletions. Am J Med Genet 1995
  5. 57(3):514-22. [CrossRef] 5. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 1999
  6. 56(10):940-5. [CrossRef] 6. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996
  7. 6(3):243-50. [CrossRef] 7. Altinyazar V, Gunderici A. Personality traits of schizophrenic patients in remission and their first-degree relatives: a dopaminergic and glutamatergic gene polymorphism study. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2013
  8. 23(2):138-48. [CrossRef] 8. Fan JB, Zhang CS, Gu NF, Li XW, Sun WW, Wang HY, et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol Psychiatry 2005
  9. 57(2):139-44. [CrossRef] 9. Munafo MR, Bowes L, Clark TG, Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol Psychiatry 2005
  10. 10(8):765-70. [CrossRef] 10. Costas J, Sanjuán J, Ramos-Ríos R, Paz E, Agra S, Ivorra JL, et al. Heterozygosity at catechol-O-methyltransferase Val158Met and schizophrenia: new data and meta-analysis. J Psychiatr Res 2011
  11. 45(1):7-14. [CrossRef] 11. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catecholO-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004
  12. 75(5):807-21. [CrossRef] 12. Bray NJ, Buckland PR, Williams NM, Williams HJ, Norton N, Owen MJ, et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 2003
  13. 73(1):152-61. [CrossRef] 13. Honea R, Verchinski BA, Pezawas L, Kolachana BS, Cal